Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

Rechercher

Affichage: 17 résultats.
    • Article de périodique
    Patient-specific Dosimetry in predicting renal toxicity with Y-90-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship
    Barone, Raffaella[UCL] Jamar, François[UCL] Pauwels, Stanislas[UCL] Borson-Chazot, FO Valkerna, R Walrand, Stéphan[UCL] Chauvin, F Gogou, Lida Kvols, LK Krenning, EP (2005) The Journal of Nuclear Medicine — Vol. 46, p. 99S-106S (2005)
    • Communication
    Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study
    Valkema, R Jamar, François[UCL] Pauwels, Stanislas[UCL] Bakker, WH Norenberg, J Smith, C Stolz, B Kvols, L Krenning, EP (2001) —
    • Communication
    Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy.
    Barone, Raffaella[UCL] Jamar, François[UCL] Pauwels, Stanislas[UCL] Walrand, Stephan[UCL] Valkema, R Kvols, L Smith, C Krenning, EP (2002) —
    • Communication
    Effect of omeprazole on renal uptake of 111-In-DTPA-octreotide
    Barone, Raffaella[UCL] Pauwels, Stanislas[UCL] Jamar, François[UCL] de Jong, M. Bernard, BF Van Gameren, A Krenning, EP (2001) —
    • Communication
    Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy.
    Jonard, P. Jamar, François[UCL] Pauwels, Stanislas[UCL] Walrand, Stéphan[UCL] Collart, JP Valkema, R Bakker, W Labar, Daniel[UCL] Smith, C Kvols, L Krenning, EP (2000) —
    • Communication
    Biodistribution of yttrium and lutetium labeled DOTATOC and DOTATATE in rat tumor models.
    Pauwels, Stanislas[UCL] Jamar, François[UCL] Barone, Raffaella[UCL] Carlier, Pascal[UCL] Bernard, HF Labar, Daniel[UCL] Krenning, EP de Jong, M. (2002) —
    • Communication
    Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors.
    Valkema, R Jamar, François[UCL] Pauwels, Stanislas[UCL] Kvols, L Bakker, WH Smith, C Krenning, EP (2002) —
    • Communication
    Intrapatient comparison between OctreoScan111 and Octreother dosimetry. Potential effectiveness and safety
    Barone, Raffaella[UCL] Jamar, François[UCL] Pauwels, Stanislas[UCL] Walrand, Stephan[UCL] De Camps, J Kvols, LK Krenning, EP Smith, C (2001) —
    • Communication
    Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study.
    Valkema, R Jamar, François[UCL] Pauwels, Stanislas[UCL] Jonard, P. Bakker, WH Norenberg, J Hadley, J Smith, C Kvols, L Krenning, EP (2000) —
    • Communication
    Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))?
    Barone, Raffaella[UCL] Jamar, François[UCL] Pauwels, Stanislas[UCL] Walrand, Stéphan[UCL] Labar, Daniel[UCL] Carlier, Pascal[UCL] Smith, C Kvols, L Krenning, EP (2000) —
    • Communication
    Peptide receptor therapy with (IN)-I-111-DTPA-octreotide (OC)
    Krenning, EP Pauwels, Stanislas[UCL] Valkema, R Kooij, PPM Breeman, WAP Bakker, WH deHerder, WW vanEijck, CHJ Kwekkeboom, D deJong, M (1997) —
    • Communication
    Somatostatin receptor: Scintigraphy and radionuclide therapy
    Krenning, EP Pauwels, Stanislas[UCL] Kooij, PPM Breeman, WAP Postema, PTE DeHerder, WW Valkema, R Kwekkeboom, DJ (1996) Meeting on Somatostatin Analogues - Basic and Clinical Perspectives — SORRENTO (Italy)
    • Communication
    Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study.
    Valkema, R Pauwels, Stanislas[UCL] Jamar, François[UCL] Kvols, L Smith, C Krenning, EP (2003) 50th Annual Meeting of the Society-of-Nuclear-Medicine — NEW ORLEANS (Louisiana)
    • Communication
    Effect of peptide amount on biodistribution of Y-86-DOTA-Tyr(3)-octreotide (SMT487).
    Jonard, P. Jamar, François[UCL] Pauwels, Stanislas[UCL] Walrand, Stéphan[UCL] Labar, Daniel[UCL] Mathieu, I Smith, C Kvols, L Krenning, EP (2000) —
    • Communication
    Peptide receptor radionuclide therapy (PRRT) with Y-90-DOTA(0),Tyr(3)-octreotide (Y-Oc) and In-111-DTPA(0)-octreotide (In-Oc): Comparison of tumor response and toxicity.
    Valkema, R Pauwels, Stanislas[UCL] Jamar, François[UCL] Kvols, L Bakker, WH Smith, C Krenning, EP (2002) —
    • Communication
    Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA,Tyr3]octreotide: Toxicity and efficacy of 4-cycle and single-cycle regimens
    Valkema, R Pauwels, Stanislas[UCL] Jamar, François[UCL] Kvols, LK Barone, Raffaella[UCL] Lasher, J Krenning, EP (2004) 40th Annual Meeting of the American-Society-of-Clinical-Oncology — New Orleans (La)
    • Communication
    Metabolic effects of amino acids (AA) solutions infused for renal radioprotection.
    Barone, Raffaella[UCL] Pauwels, Stanislas[UCL] Jamar, François[UCL] De Camps, J Smith, C Kvols, L Krenning, EP (2000) —